nach oben

CNS Drugs

Erschienen in:

01.07.2004 | Review Article

Pharmacotherapy of Alcohol Dependence

A Review of the Clinical Data

verfasst von: Professor Karl Mann

Erschienen in: CNS Drugs | Ausgabe 8/2004

Einloggen, um Zugang zu erhalten

Abstract

Over the last 20 years, the role of adjuvant pharmacotherapy in optimising outcome in rehabilitation programmes for alcohol-dependent patients has become increasingly evident. New avenues for rational drug treatment have arisen from better understanding of the neurobiological substrates of alcohol dependence, including adaptive changes in amino acid neurotransmitter systems, stimulation of dopamine and opioid peptide systems, and, possibly, changes in serotonergic activity.

Disulfiram, naltrexone and acamprosate are currently the only treatments approved for the management of alcohol dependence. However, there is still no unequivocal evidence from randomised controlled clinical trials that disulfiram improves abstinence rates over the long term. Aversive therapy with disulfiram is not without risk for certain patients, and should be closely supervised. Both naltrexone and acamprosate improve outcome in rehabilitation of alcohol-dependent patients, but seem to act on different aspects of drinking pathology. Naltrexone is thought to decrease relapse to heavy drinking by attenuating the rewarding effects of alcohol. However, data from the naltrexone clinical trial programme are somewhat inconsistent, with several large studies being negative. Acamprosate is believed to maintain abstinence by blocking the negative craving that alcohol-dependent patients experience in the absence of alcohol. The clinical development programme has involved a large number of patients and studies, of which the vast majority have shown a beneficial effect of acamprosate on increasing abstinence rates. Both drugs are generally well tolerated; nausea is reported by around 10% of patients treated with naltrexone, while the most frequent adverse effect reported with acamprosate is diarrhoea.

Another opioid receptor antagonist, nalmefene, has shown promising activity in pilot studies, and may have a similar profile to naltrexone. Data from studies of SSRIs in alcohol dependence are somewhat heterogeneous, but it appears that these drugs may indirectly improve outcome by treating underlying depression rather than affecting drinking behaviour per se. Similarly, the anxiolytic buspirone may act by ameliorating underlying psychiatric pathology. Dopaminergic neuroleptics, benzodiazepines and antimanic drugs have not yet demonstrated evidence of activity in large controlled clinical trials. Trials with drugs acting at serotonin receptors have yielded disappointing results, with the possible exception of ondansetron.

Because the biological basis of alcohol dependence appears to be multifactorial, the future of management of alcoholism may be combination therapy, using drugs acting on different neuronal pathways, such as acamprosate and naltrexone. Pharmacotherapy should be used in association with appropriate psychosocial support and specific treatment provided for any underlying psychiatric comorbidities.

Maisto SA, Connors GJ, Zywiak WH. Alcohol treatment, changes in coping skills, self-efficacy, and levels of alcohol use and related problems 1 year following treatment initiation. Psychol Addict Behav 2000; 14: 257–66PubMed

Faingold CL, N’gouemo P, Riaz A. Ethanol and neurotransmitter interactions: from molecular to integrative effects. Prog Neurobiol 1998; 55: 509–35PubMed

Koob GF, Roberts AJ, Schulteis G, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998; 22: 3–9PubMed

Spanagel R, Zieglgänsberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 1997; 18: 37–65

Samson HH, Harris RA. The neurobiology of alcohol abuse. Trends Pharmacol Sci 1992; 13: 206–11PubMed

Grobin AC, Matthews DB, Devaud LL, et al. The role of GABAA receptors in the acute and chronic effects of ethanol. Psychopharmacology 1998; 139: 2–19PubMed

Olds ME, Fobes JL. The central basis of motivation: intracranial self-stimulation studies. Annu Rev Psychol 1981; 32: 523–74PubMed

Gessa GL, Muntoni F, Collu M, et al. Low doses of ethanol activate dopaminergic neurons in the ventral tegemental area. Brain Res 1985; 348: 201–3PubMed

Benjamin D, Grant E, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993; 621: 137–40PubMed

10.

Gianoulakis C. Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol 1996; 31Suppl. 1: 33–42PubMed

11.

Cardoso RA, Brozowski SJ, Chavez-Noriega LE, et al. Effects of ethanol on recombinant human neuronal nicotinic acetyl-choline receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999; 289: 774–80PubMed

12.

Söderpalm B, Ericson M, Olausson P, et al. Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav Brain Res 2000; 113: 85–96PubMed

13.

Arendt F. Impairment in memory function and neurodegenerative changes in the cholinergic forebrain system induced by chronic intake of ethanol. J Neural Transm 1994; 44: 173–87

14.

Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. Trends Pharmacol Sci 1992; 13: 69–75PubMed

15.

Soubrié P. Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci 1986; 9: 319–64

16.

Modell JG, Glaser FB, Cyr L, et al. Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence. Alcohol Clin Exp Res 1992; 16: 272–4PubMed

17.

Anton RF, Moak DH, Latham P. The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behaviour. Alcohol Clin Exp Res 1995; 19: 92–9PubMed

18.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994

19.

Lehert P. Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol Suppl 1993; 2: 157–63

20.

Mundle G, Ackermann K, Munkes J, et al. Influence of age, alcohol consumption and abstinence on the sensitivity of carbohydrate-deficient transferrin, gamma-glutamyltransferase and mean corpuscular volume. Alcohol Alcohol 1999; 34: 760–6PubMed

21.

Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281: 1318–25PubMed

22.

Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986; 256: 1449–55PubMed

23.

O’Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49: 881–7PubMed

24.

Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876–80PubMed

25.

Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734–9PubMed

26.

Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology 1998; 139: 44–52PubMed

27.

Gastpar M, Bonnet U, Boning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002; 22: 592–8PubMed

28.

Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 2002; 26: 1381–7PubMed

29.

Kranzler HR, Modesto-Lowe V, Van Kirk JR. Naltrexone vs nefazodone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology 2000; 22: 493–503PubMed

30.

Chick J, Anton R, Checinski K, et al. A multicentre, randomised, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence in adults. Alcohol Alcohol 2000; 35: 587–93PubMed

31.

Anton RF, Moak DH, Waid R, et al. Naltrexone and cognitive behavioral therapy of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156: 1758–64PubMed

32.

Heinälä P, Alho H, Kiianmaa K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 2001; 21: 287–92PubMed

33.

Balldin J, Berglund M, Borg S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 2003; 27: 1142–9PubMed

34.

Monti PM, Rohsenow DJ, Hutchison KE, et al. Naltrexone’s effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 1999; 23: 1386–94PubMed

35.

Morris PL, Hopwood M, Whelan G, et al. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001; 96: 1565–73PubMed

36.

Latt NC, Jurd S, Houseman J, et al. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 2002; 176: 530–4PubMed

37.

Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54: 737–42PubMed

38.

Oslin D, Liberto JG, O’Brien J, et al. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 1997; 5: 324–32PubMed

39.

Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 1998; 22: 1074–9PubMed

40.

Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60: 92–9PubMed

41.

McCaul ME, Wand GS, Eissenberg T, et al. Naltrexone alters subjective responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 2000; 22: 480–92PubMed

42.

Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001; 25: 1634–47PubMed

43.

Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 2000; 24: 1542–9PubMed

44.

Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 2001; 36: 2–10PubMed

45.

Streeton C, Whelan G. Naltrexone, a relapse-prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001; 36: 544–52PubMed

46.

Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25: 1335–41PubMed

47.

Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2000; (3): CD001867

48.

O’Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996; 53: 217–24PubMed

49.

Anton RF, Moak DH, Latham PK, et al. Posttreatment results of combining naltrexone and cognitive behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 2001; 21: 72–7PubMed

50.

Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 2000; 60: 343–62PubMed

51.

Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 2000; 149: 327–44PubMed

52.

Chick J, Howlett H, Morgan MY, et al. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000; 35: 176–87PubMed

53.

Lhuintre JP, Moore ND, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990; 25: 613–22PubMed

54.

Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30: 239–47PubMed

55.

Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438–42PubMed

56.

Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000; 35: 202–9PubMed

57.

Barrias JA, Chabac S, Ferreira L, et al. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clinica 1997; 18: 149–60

58.

Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001; 36: 413–8PubMed

59.

Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate: results from a placebo controlled study in alcohol dependence. Arch Gen Psychiatry 1996; 53: 673–80PubMed

60.

Geerlings PJ, Ansoms C, Van Der Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 1997; 3: 129–37

61.

Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997; 92: 1537–46PubMed

62.

Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. Br J Psychiatry 1997; 170: 73–7

63.

Namkoong K, Lee BO, Lee PG, et al. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003; 38: 135–41PubMed

64.

Roussaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics. J Pharm Belg 1996; 51: 65–8PubMed

65.

Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998; 22: 573–9PubMed

66.

Pelc I, Le Bon O, Verbanck P, et al. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients; a placebo controlled double-blind multi-centre study. In: Naranjo C, Sellers E, editors. Novel pharmacological interventions for alcoholism. New York, USA: Springer Verlag, 1992: 348–52

67.

Lhuintre JP, Daoust M, Moore ND, et al. Ability of calcium acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985; I: 1014–6

68.

Ladewig D, Knecht T, Lehert P, et al. Acamprosate: a stabilising factor in long-term withdrawal of alcoholic patients. Ther Umsch 1993; 50: 182–8PubMed

69.

Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in maintaining abstinence in alcohol-dependent individuals: results of a meta-analysis. J Stud Alcohol 2004 Jan; 65(1): 136–9

70.

Rubio G, Jiménez-Arriero MA, Ponce G, et al. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001; 36: 419–25PubMed

71.

Gerra G, Caccavari R, Delsignore R, et al. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and non-familial alcoholic patients. Curr Ther Res 1992; 52: 291–5

72.

Pelc I, Ansoms C, Lehert P, et al. The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modelling of therapy success prediction. Alcohol Clin Exp Res 2002; 26: 1529–38PubMed

73.

De Wildt WAJM, Schippers GM, Van den Brink W, et al. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol Alcohol 2002; 4: 375–82

74.

Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994; 18: 1162–7PubMed

75.

Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56: 719–24PubMed

76.

Mäkelä R, Kallio A, Karhuvaara S, et al. Nalmefene in the treatment of heavy drinkers [abstract]. International Society of Addiction Medicine (ISAM) 2001 Sep 12–14: Trieste 2001

77.

Noble EP. Alcoholism and the dopaminergic system: a review. Addict Biol 1996; 1: 333–48PubMed

78.

Peters DH, Faulds D. Tiapride: a review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994; 47: 1010–32PubMed

79.

Shaw GK, Waller S, Majumdar SK, et al. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994; 165: 512–23

80.

Shaw GK, Majumdar SK, MacGarvie J, et al. Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry 1987; 150: 164–8PubMed

81.

Wiesbeck GA, Weijers JG, Lesch OM, et al. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled trial. Alcohol Alcohol 2001; 36: 329–34PubMed

82.

Marra D, Warot D, Berlin I, et al. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol Clin Exp Res 2002; 26: 1545–52PubMed

83.

Linnoila M, Eckardt M, Durcan M, et al. Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacol Bull 1987; 23: 452–7PubMed

84.

McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with major depression. Arch Gen Psychiatry 1996; 53: 232–40PubMed

85.

Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275: 761–7PubMed

86.

Gorelick DA, Paredes A. Effects of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992; 16: 261–5PubMed

87.

Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391–7PubMed

88.

Janiri L, Gobbi G, Manneli P, et al. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol 1996; 11: 109–17PubMed

89.

Kabel DI, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol-dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 1996; 20: 780–4PubMed

90.

Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 700–5PubMed

91.

Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry 1998; 44: 633–7PubMed

92.

Pettinati HM, Volpicelli JR, Luck G, et al. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001; 21: 143–53PubMed

93.

CoŞkunol H, Gökden O, Sabri Ercan E, et al. Long-term efficacy of sertraline in the prevention of alcoholic relapses in alcohol-dependent patients: a single-center, double-blind, randomized, placebo-controlled, parallel-group study. Curr Ther Res 2002; 63: 759–71

94.

Gual A, Balcells M, Torres M, et al. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol Alcohol 2003; 38: 619–25PubMed

95.

Naranjo CA, Bremner KE, Lanctot KA. Effects of citalopram and a brief psychosocial intervention on alcohol intake, dependence and problems. Addiction 1995; 90: 87–99PubMed

96.

Tiihonen J, Ryynanen DP, Kauhanen J, et al. Citalopram in the treatment of alcoholism. Pharmacopsychiatry 1996; 29: 27–9PubMed

97.

Johnson BA, Jasinski DR, Galloway GP, et al. Ritanserin in the treatment of alcohol dependence: a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology 1996; 128: 206–15

98.

Wiesbeck GA, Weijers JG, Chick J, et al. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled, double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 1999; 23: 230–5PubMed

99.

Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18: 879–85PubMed

100.

Johnson BA, Roace JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomised clinical trial. JAMA 2000; 284: 1016–7

101.

Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989; 22: 49–59PubMed

102.

Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 1992; 12: 19–26PubMed

103.

Malcolm R, Anton RF, Randall CL, et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992; 16: 1007–13PubMed

104.

Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 1994; 51: 720–31PubMed

105.

Malec TS, Malec EA, Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 1996; 20: 853–8PubMed

106.

Malec TS, Malec EA, Gagne MA, et al. Efficacy of buspirone in alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res 1996; 20: 309–12

107.

Messiha FS, Butler D, Adams MK. Carbamazepine and ethanol elicited responses in rodents. Alcohol 1986; 3: 131–3PubMed

108.

Alexander GJ, Alexander RB. Alcohol comsumption in rats treated with lithium carbonate or rubidium chloride. Pharmacol Biochem Behav 1978; 8: 533–6PubMed

109.

Doras W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA 1989; 262: 1646–52

110.

Mueller TI, Stout RL, Rudden S, et al. A double-blind placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 1997; 21: 86–91PubMed

111.

Gallimberti L, Ferri M, Ferrara SD, et al. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res 1992; 16: 673–6PubMed

112.

Ait-Daoud N, Johnson BA, Prihoda TJ, et al. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology 2001; 154: 23–7PubMed

113.

Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drags 1997; 53: 1038–53

114.

Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry 1997; 54: 1130–5PubMed

115.

Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999; 20: 427–35PubMed

116.

Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drag abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511–8PubMed

117.

Kessler RC, Cram RM, Warber LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54: 313–21PubMed

118.

Swift RM. Drag therapy for alcohol dependence. N Engl J Med 1999; 340: 1482–7PubMed

Titel: Pharmacotherapy of Alcohol Dependence
A Review of the Clinical Data
verfasst von: Professor Karl Mann
Publikationsdatum: 01.07.2004
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 8/2004
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200418080-00002

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen